Solara Active Pharma Sciences Limited has informed the Exchange regarding a press release dated July 25, 2025, titled "Solara Q1'26 performance" of the Board Meeting held today i.e. July 25, 2025, to consider the Financial Results for the quarter ended June 30, 2025.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.3 pts more than Nifty Microcap 250 and 6.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Solara Active Pharma Sciences reported Q1 FY26 revenue of INR 3,201 Mn, down 12% YoY but up 15% QoQ from INR 2,790 Mn. Gross margin stood at 54.1%, expanding sharply by 960 basis points YoY, while EBITDA margin rose 639 bps YoY to 18.0%, with EBITDA at INR 575 Mn (up 36% YoY). The company swung to a profit of INR 105 Mn from a loss of INR 135 Mn in Q1 FY25, marking its highest PAT in 12+ quarters. Gross debt was reduced from INR 7,760 Mn to INR 6,327 Mn using rights issue proceeds and operating cash flows. The company also announced a proposed carve-out of its CRAMS and Polymers business into a new entity called 'Synthix Global Pharma Solutions Limited'.
Strong margin expansion, return to profitability, and meaningful debt reduction are positive signals for shareholders. However, the 12% YoY revenue decline and the pending CRAMS demerger (subject to shareholder approval) introduce near-term uncertainty around the business structure and growth trajectory.